Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
NRNeuroSense Therapeutics Ltd. logo

NeuroSense Therapeutics Ltd. (NRSN)

NASDAQ Capital Market · Currency in USD
$2.46 ▲ +0.02 (+0.82%)
At close: Oct 23, 4:00 PM ET. Market closed.
$2.42 ▼ -0.04 (-1.63%)
After hours: Oct 23, 4:35 PM ET

Summary

Previous Close
$2.44
Open
$2.49
Day's Range
$2.40 – $2.55
52 Week Range
$2.15 – $25.40
Volume
11,153
Avg. Volume
20,379
Market Cap
$4.67M
Beta (5Y Monthly)
1.64
PE Ratio (TTM)
--
EPS (TTM)
-$6.86
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: NeuroSense Therapeutics Ltd.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
17
CEO
Alon Ben-Noon

NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease.

Earnings

DateEst.Actual
Sep 25, 2026-$3.90-$2.06Beat
Jun 30, 2026-$3.90-$3.90Beat
Mar 31, 2026-$0.07-$0.24Miss
Dec 17, 2025-$0.87-$2.60Miss
Aug 1, 2025-$0.22-$0.14Beat
Apr 7, 2025-$0.10-$0.06Beat

Analyst view

Rating: Buy
Buy 67% · Hold 33% · Sell 0%

Get free alerts on NRSN and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.